<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20180627040251N13</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2025-07-29</date_registration>
      <primary_sponsor>Kharazmi University</primary_sponsor>
      <public_title>"Effect of Strength-Balance Exercises, Virtual Reality, and Combined Exercises on Neuroplasticity, Quality of Life, Balance, and Fall Risk in Parkinson's Disease"</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of Strength-Balance Exercises, Virtual Reality-Based Exercises, and Combined Exercises on Neuroplasticity, Quality of Life, Balance, and Fall Risk in Patients with Parkinson's Disease</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2025-08-01</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>48</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/84702</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: After the initial assessment of the participants, randomization was carried out based on four-block randomization. Participants are randomly assigned to one of two groups using four-block randomization. One of the research team members, who is not involved in the sample selection process, determines the random allocation sequence using the online tool (randomizer.org). Sealed opaque envelopes containing the randomization sequence will be used for allocation concealment, Blinding description: In this study, the outcome assessor is blind to the groups’ randomization and interventions receiving by participants. in this way, during the evaluation before and after the intervention protocol, they do not make mistakes in their judgments in favor of a specific therapeutic intervention.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Parkinson's Disease.</hc_freetext>
      <i_freetext>Intervention 1: Group 1 (Strength-Balance Exercises):Participants in this group receive strength and balance exercises three times a week for 8 weeks. The exercises include resistance training using weights to strengthen lower limb muscles and balance exercises such as standing on balance boards and performing dynamic movements to improve coordination and stability. Intervention 2: Intervention group: Group 2 (Virtual Reality-Based Exercises):Participants in this group use virtual reality systems to perform balance and movement exercises. These exercises are designed in simulated virtual environments, and patients perform balance and coordination tasks under the supervision of a physiotherapist. Each session lasts 30 minutes, and the exercises are performed three times a week for 8 weeks. Intervention 3: Intervention group: Intervention Group 3 (Combined Exercises):This group receives a combination of strength-balance exercises and virtual reality-based exercises. Participants perform 30 minutes of strength and balance exercises followed by 30 minutes of virtual reality-based exercises in each session. The sessions are conducted three times a week for 8 weeks. Intervention 4: Control group: Intervention group: Control Group:The control group receives no intervention and only undergoes standard treatment protocols.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no additional information available</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Aryan Omidi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 12, Allameh Jafari St., Tohid Town, Sabzevar County, Razavi Khorasan, Iran</address>
        <city>sabzevar</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9617984797</zip>
        <telephone>+98 51 4441 0962</telephone>
        <email>aryan.omidi2911@gmail.com</email>
        <affiliation>kharazmi university</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Hassan Sadeghi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Faculty of Physical Education and Sports Sciences, Shahid Keshvari Complex, Shahid Hesari St., Mirdamad, Tehran, Iran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1544733111</zip>
        <telephone>+98 21 2222 8001</telephone>
        <email>hassan.sadeghi81@yahoo.com</email>
        <affiliation>Kharazmi University</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients diagnosed with Parkinson’s disease confirmed by a specialist doctor.
Individuals aged between 50 and 70 years.
Patients with moderate to severe symptoms based on the UPDRS-III scale.
Individuals capable of performing physical exercises according to the study protocol.
Individuals who have signed a written consent form to participate in the study.</inclusion_criteria>
      <agemin>50 years</agemin>
      <agemax>75 years</agemax>
      <gender>Male</gender>
      <exclusion_criteria>Individuals with neurological disorders other than Parkinson’s disease (such as Alzheimer’s or stroke).
Individuals with severe psychiatric conditions that impair their ability to participate in exercises.
Individuals currently undergoing active or continuous physical therapy.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>G20</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Parkinson's disease</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Group 1 (Strength-Balance Exercises):Participants in this group receive strength and balance exercises three times a week for 8 weeks. The exercises include resistance training using weights to strengthen lower limb muscles and balance exercises such as standing on balance boards and performing dynamic movements to improve coordination and stability.</i_keyword>
      <i_keyword>Intervention group: Group 2 (Virtual Reality-Based Exercises):Participants in this group use virtual reality systems to perform balance and movement exercises. These exercises are designed in simulated virtual environments, and patients perform balance and coordination tasks under the supervision of a physiotherapist. Each session lasts 30 minutes, and the exercises are performed three times a week for 8 weeks.</i_keyword>
      <i_keyword>Intervention group: Intervention Group 3 (Combined Exercises):This group receives a combination of strength-balance exercises and virtual reality-based exercises. Participants perform 30 minutes of strength and balance exercises followed by 30 minutes of virtual reality-based exercises in each session. The sessions are conducted three times a week for 8 weeks.</i_keyword>
      <i_keyword>Control group: Intervention group: Control Group:The control group receives no intervention and only undergoes standard treatment protocols.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Neuroplasticity. Timepoint: The measurement of outcome variables is conducted at two time points:Before the intervention (Pre-test)After the intervention (Post-test). Method of measurement: Neuroplasticity: Electroencephalogram (EEG).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Quality of Life:To assess the quality of life in Parkinson's patients. Timepoint: immediately before intervention; immediately after intervention. Method of measurement: PDQ-39.</sec_outcome>
      <sec_outcome>Balance. Timepoint: mmediately before intervention; immediately after intervention. Method of measurement: -Single Leg Stance Test--TUG test.</sec_outcome>
      <sec_outcome>Fall risk. Timepoint: immediately before intervention; immediately after intervention. Method of measurement: BBS test.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Kharazmi University</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2025-04-20</approval_date>
        <contact_name>Research Ethics Committees of kharazmi university</contact_name>
        <contact_address>Shahid Keshvari Sports Complex, Kosha Street, between Shohareh and Hesari, Shahid Haghani Highway, Tehran (Mirdamad neighborhood) Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
